Dr. med. Michel Haig Maillard Service of Gastroenterology

Dr. med. Michel Haig Maillard Service of Gastroenterology and Hepatology Centre Hospitalier Universitaire Vaudois (CHUV) BH10-­‐535 Rue du Bugnon 46 1011 Lausanne, VD Tel +4121-­‐3140716 Cell +4179-­‐5562193 [email protected] Current institutional and academic qualification and function March 2012-­‐ present. Staff physician (Chef de clinique). Service de gastroentérologie et d’hépatologie, Département de médecine, CHUV, Lausanne. Doctor in Medicine and Life Sciences (M.D.-­‐Ph.D.): Regulatory T cell defects are associated with autoimmunity in Wiskott-­‐Aldrich syndrome protein deficient mice, 2008, UNIL-­‐FBM, Lausanne. Doctor in Medicine (M.D.): Chimeric anti-­‐TNFα antibody (infliximab) administration as a treatment of fistulizing and active Crohn’s disease, 2002, UNIL-­‐FBM, Lausanne. Undergraduate Education 2003-­‐2008: M.D.-­‐Ph.D. graduate student. UNIL-­‐FBM, Lausanne. Thesis project conducted at Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 1993-­‐1999: Medical School. UNIL-­‐FBM, Lausanne, Switzerland Post-­‐graduate Education a.
Main courses/employment before obtaining doctorate and/or specialist qualification
Senior Fellow (Chef de clinique adjoint), April 2011 to March 2012. Service de
gastroentérologie et d’hépatologie, Département de médecine, CHUV, Lausanne. Prof. D.
Moradpour.
Clinical Fellow, Oct 2007 to April 2008 and April 2009 to April 2011. Service de
gastroentérologie et d’hépatologie, Département de médecine, CHUV, Lausanne. Profs. P.
Michetti and D. Moradpour.
Research Fellow, 2004-2007, Massachusetts General Hospital, Harvard Medical School,
Boston, MA, USA.
Bachelor in Biology, 2004, UNIL-FBM, Lausanne. The role of the peroxisome-proliferatoractivated receptor β in fat metabolism and leptin expression. Centre intégratif de génomique
(CIG). Prof. B. Desvergnes.
Resident, Oct 2002 to Dec 2003 and April 2008 to April 2009. Department of Internal
Medicine, CHUV, Lausanne. Prof. P. Nicod.
Resident, Oct 2001 to Sept 2002. Internal Medicine and Intensive Care Unit, St-Loup
Hospital, Pompaples, Switzerland. Dr. A. Zwahlen.
Intern, Oct 2000 to Sept 2001. Surgery and Orthopedics, St-Loup Hospital, Pompaples,
Switzerland. Dr. P. Saillen.
b.
Post-doctorate and/or post-speciality courses/employment
2014, Co-investigator clinical research course. CHUV, Lausanne.
2009, Advanced IBD Postgraduate Course. European Crohn’s and Colitis Organisation,
Hamburg, Germany.
2008-2009, Postdoctoral fellowship. Service de gastroentérologie et d’hépatologie,
Département de médecine. CHUV, Lausanne. D. Velin, MER1 and Prof. P. Michetti.
Awards
2014, IBD award of the Swiss Gastroenterology Association (SGG-SSG), Switzerland
2011, Abbott IBD Award, Switzerland
2010, Travel award. United European Gastroenterology Federation Teaching Activity on Basic
Science. Cambridge, UK
2010, Best abstract. Fifth Congress of the European Crohn’s and Colitis Organisation,
Prague, Czech Republic
2009, SwissIBD Days Research Award, Switzerland
2005, Imedex Travel Award, 4th Annual Advances in Inflammatory Bowel Diseases, Miami,
FL, USA
Scientific or technical functions
Co-President of the Scientific committee and collaborator of the Swiss IBD Cohort Study
Steering Committee member, IBDnet, Switzerland
Executive committee member, Swiss Study Group for Coloproctology
Grant and abstract reviewer for the European Crohn’s and Colitis Organisation
Reviewer (journals with editorial policy): Mucosal Immunology, Inflammatory Bowel Diseases,
Clinical Immunology, PlosOne, Expert review of Gastroenterology & Hepatology
Scientific societies
2014 to date. Member, Swiss Gastroenterology Society (SGG-SSG)
2013 to date. Member, IBDnet, Switzerland
2008 to date. Member, European Crohn’s and Colitis Organisation (ECCO)
2006-2010. Member, American Gastroenterology Association (AGA)
2006-2009. Member, Crohn’s and Colitis Foundation of America
Lecture invitations
1.
Sept 12, 2014. Speaker. Toll-interacting Protein Modulates Colitis Susceptibility. IBD award
of the Swiss Gastroenterology Association (SGG-SSG), Switzerland.
2.
Sept 11, 2014. Speaker. Cholangioscopie au nasofibroscope : L’expérience Lausannoise.
Swiss Gastroenterology Association (SGG-SSG) & ASPE-SVPE Congress. Interlaken.
3.
June 11, 2014. Speaker. Maladie coeliaque: Mise au point. Groupement hospitalier de
l’ouest Lausannois, Hôpital de Nyon.
4.
May 13, 2014. Speaker. Use of anti-TNF trough level measurements in IBD monitoring.
Formation post-graduée. Fondation de l’Hermitage, Lausanne.
5.
April 8, 2014. Speaker. Colloque multidisciplinaire d’immunologie. CHUV, Lausanne
6.
March 27, 2014. Speaker. Maladies inflammatoires chroniques : Le dosage des
médicaments anti-TNF est-il utile pour le clinicien ? Conference organised by Unilabs. Hôtel
de la Paix, Genève.
7.
March 2014. Speaker. Update on celiac disease and lactose intolerance. Formation continue
pour les internistes et généralistes du Lavaux. Hôpital de Lavaux, Cully.
8.
Jan 2014. Speaker. Extraintestinal manifestations of IBD. Journée d’information aux
patients, Hôpital de Neuchâtel-Pourtales, Neuchâtel.
9.
Jan 2014. Speaker. Fistulizing Crohn’s disease : limits of the medical therapy. 35e journée
suisse de coloproctologie, Bern, Lausanne
10. Nov 2013. Speaker. L’intestin ou notre 2e cerveau. Congrès du groupe Suisse des médecins
travaillant en EMS. Signal de Bougy, Switzerland
11. Nov 2013. Speaker. Therapeutic monitoring in IBD using anti-TNFα levels. Swiss pediatric
gastroenterology meeting. Bern, Switzerland.
12. Sept 2013. Speaker. Coeliaquie update. Journées d’automne
gastroentérologie et hépatologie, CHUV, Lausanne, Switzerland
d'actualités
en
13. Sept 2013. Speaker. Therapeutic monitoring in IBD: measuring metabolites, anti-TNFα
levels and beyond. ECCO Workshop. Emmetten, Switzerland
14. July 2013. Organizer and speaker. Fistulizing Crohn’s
interdisciplinaire. Hôtel Barcarolle, Prangins, Switzerland
disease.
Table
ronde
15. April 2013. Speaker. Role of Tollip in inflammation, microbiota composition and cancer
development. CIIL Seminars, Epalinges, Switzerland
16. Sept 2012. Speaker. Monitoring de la réponse aux traitements dans les maladies
inflammatoires intestinales, Symposium sur les maladies inflammatoires, CHUV, Lausanne
17. Feb 2012. Speaker. Prise en charge aux urgences des maladies inflammatoires intestinales.
CHUV, Lausanne
18. Jan 2012. Speaker. Case presentation. Minisymposium challenges in viral hepatitis. CHUV,
Lausanne
19. Oct 2010. Speaker. Toll-Interacting Protein Deficiency Leads to Increased Susceptibility to
Acute and Chronic Colitis. “REMIND” (“Recherche sur les Maladies Inflammatoires
Digestives”) working group, Lyon, France
20. Sept 2009. Speaker. Proctite réfractaire. Journées d’automne, Lausanne, Switzerland
21. April 2009. Speaker. SwissIBD Days, Nottwil, Switzerland
22. April 2008. Speaker. SwissIBD Days, Posieux, Switzerland
Conference papers
1.
Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B,
Froehlich F, Michetti P, Pittet V. Appropriateness and Long-term Discontinuation Rate of
Biological Therapies in Ulcerative Colitis. 9th Congress of ECCO. Copenhagen, February 2022, 2014. (Abstract published in Journal of Crohn’s and Colitis 2014; 8: S299-S300)
2.
Pittet V, Schoepfer A, Maillard MH, Mottet C, Gonvers JJ, Felley CP, Burnand B, Michetti P,
Froehlich F, Vader JP. When to Stop Therapy in Crohn's Disease? Results of the EPACT-2
Update Panel. Digestive Disease Week 2013. Orlando, Florida, May 18-21, 2013. (Abstract
published in Gastroenterology 2013 ; 144(5) : S580-581)
3.
Toll-Interacting Protein Modulates Gut Flora Composition, Epithelial Barrier Integrity and
Susceptibility to Colitis. Maillard MH, Grandjean T, Uhlig HH, Barnich N, Longet S,
Corthésy B, Michetti P, Chamaillard M and Velin D. [Oral presentation].Annual SGG/SSG
Congress 2012. Interlaken, September 20-21, 2012
4.
Pittet V, Vader JP, Gonvers JJ, Maillard MH, Schoepfer A, Felley C, Mottet C, Michetti P,
Froehlich F. First explicit criteria to decide on the appropriateness of therapy of ulcerative
colitis: The European EPATUC Panel. 7th Congress of ECCO. Barcelona, Spain. February 1618. 2012. (Abstract published in Journal of Crohn’s and Colitis 2012 ; 6 : S141)
5.
First Explicit Criteria to Decide on the Appropriateness of Therapy of Ulcerative Colitis: the
European EPATUC Panel. Pittet V, Vader JP, Gonvers JJ, Maillard MH, Schoepfer A, Felley
C, Mottet C, Michetti P, Froehlich F. Digestive Disease Week 2012. San Diego, USA, May
19-22, 2012. (Abstract published in Gastroenterology 2012 ; 142 (5) : S224)
6.
Toll-Interacting Protein Deficiency Modulates Flora Composition and Susceptibility to Colitis.
Maillard MH, Chamaillard M, Uhlig HH, Barnich N, Pythoud C, Bachmann D, Michetti P and
Velin D. [Oral presentation]. International Congress of Mucosal Immunology (ICMI), Paris,
France. July 5-9. 2011.
7.
Citrobacter rodentium Requires Intestinal Neural Wiskott-Aldrich Syndrome Protein (NWASp) for Actin Pedestal Formation, Colonization and Epithelial Barrier Disruption In Vivo.
Garber JJ, Shi HN, Nguyen DD, Maillard MH, Mallick E, Leong JM, Snapper SB. [Oral
presentation]. Digestive Disease Week. Chicago, Illinois. May 7-11. 2011. (Abstract
published in Gastroenterology 2011; 140(5) : S646.)
8.
Toll-Interacting Protein Deficiency Leads to Increased Susceptibility to Acute and Chronic
Colitis. Maillard MH, Bernasconi E, Uhlig HH, Andriamaha C, Bachmann D, Bouzourène H,
Burns K, Michetti P, Velin D. [Oral presentation]. SGG/SSG congress. Interlaken,
Switzerland. October 5. 2010.
9.
Toll-Interacting Protein Deficiency Leads to Increased Susceptibility to Acute and Chronic
Colitis. Maillard MH, Uhlig HH, Barnich N, Pythoud C, Bachmann D, Michetti P and Velin D.
[Oral presentation. Best abstract] Fifth congress of the ECCO. Prague, Czech Republic.
February 25-27. 2010 (Abstract published in Journal of Crohn's and Colitis Supplements.
2010; 4(1):26)
10. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that
promote efficient colonic mucosal Healing. Velin D, Bernasconi E, Favre L, Maillard MH,
Bouzourene H, Parkinson J, Michetti P. Fifth congress of the ECCO. Prague, Czech Republic.
February 25-27. 2010 (Abstract published in Journal of Crohn's and Colitis Supplements.
2010; 4(1):26)
11. Neural Wiskott-Aldrich Syndrome Protein is Required for the Pathogenesis of Citrobacter
rodentium In Vivo. Garber JJ, Shi HN, Nguyen DD, Maillard MH, Snapper SB. Digestive
Disease Week. New Orleans, Louisiana. May 1-5. 2010. (Abstract published in
Gastroenterology 2010; 138(5) : S84-85)
12. Intestine Specific Deletion of N-WASP Leads to Alteration of Gut Homeostasis in Mice.
Garber JJ, Nguyen DD, Maillard MH, Mizoguchi E, Bhan AK, Snapper SB. Digestive Disease
Week. Chicago, Illinois. May 30-June 4. 2009. (Abstract published in Gastroenterology
2009; 136(5): A66)
13. Regulatory T Cell-Based Cellular Therapy Prevents Colitis in WASP-Deficient Mice. Maillard
MH, Boden EK, Nguyen DD, Snapper SB. Digestive Disease Week. San Diego, California.
May 17-22. 2008. (Abstract published in Gastroenterology 2008; 134(4) : A517-A518)
14. Abnormal Innate Immune Cells Can Induce Colitogenicity in Normal Adaptive Immune
Cells. Nguyen DD, Boden EK, Maillard MH, Nagler CR, Snapper SB. Digestive Disease
Week. San Diego, California. May 17-22. 2008. (Abstract published in Gastroenterology
2008; 134(4): A43)
15. Regulatory T cell-based cellular therapy prevents colitis in WASP deficient mice. Maillard
MH, Nguyen DD, Boden E, Snapper SB. [Oral presentation]. 6th Annual Advances in
Inflammatory Bowel Diseases. Miami, Florida. December 7-9. 2007
16. A Role for the Wiskott-Aldrich Syndrome Protein in the Recruitment and Homing of
CD4+CD25+Foxp3+ Regulatory T Cells to Peripheral Lymphoid Organs. Maillard MH,
Cotta-de-almeida V, Nguyen DD, Michetti PF, Snapper SB. [Oral presentation]. Digestive
Disease Week. Washington DC, Maryland. May 19-24. 2007. (Abstract published in
Gastroenterology 2007; 132(4), Suppl S1, A142)
17. WASP-deficiency in mice leads to global regulatory T cell dysfunction with IL-10 deficiency
and aberrant IL-2 signaling independent of immune synapse formation. Maillard MH,
Cotta De Almeida V, Michetti P, Nagler C, Snapper S. Digestive Disease Week. Los Angeles,
California. May 20-25. 2006. (Abstract published in Gastroenterology 2006;130 (4), A113
(778)
18. WASP-Deficiency in Mice Leads to Global Regulatory T Cell Dysfunction with IL-2 and IL-10
Deficiency. Maillard MH, Cotta De Almeida V, Nagler C, Michetti P, Snapper S.
International congress of mucosal immunology (ICMI). Boston, Massachussetts. July 2006.
(Abstract published in Journal of Immunology 2006 Apr ;176, S137).
Publications
Original articles
00. Allam R, Maillard MH, Tardivel A, Wang Yu C, Schneider P, Velin D and Maslowski KD.
Epithelial Naips protect against colonic tumorigenesis. Under revision in J Exp Med.
01. Pittet V, Maillard MH, Burnand B, Michetti P, Froehlich F, Mottet C. Acceptance of
inflammatory bowel disease treatment recommendations based on appropriateness ratings:
Do practicing gastroenterologists agree with experts? Under revision in J Crohn’s & Colitis
1.
Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B,
Froehlich F, Michetti P, Pittet V. Appropriateness and long-term discontinuation rate of
biological therapies in ulcerative colitis. J Crohns Colitis 2014, 8:825-34.
2.
Maillard MH*, Bega H, Uhlig H, Barnich N, Grandjean T, Chamaillard M, Michetti P and
Velin D*. Toll-interacting protein modulates colitis susceptibility in mice. Inflamm Bowel
Dis 2014;20:660-70. * corresponding authors
3.
Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B,
Michetti P, Schoepfer A. When do we dare to stop biological or immunomodulatory
therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J
Crohns Colitis 2013;7:820-6.
4.
D'Angelo F, Bernasconi E, Schäfer M, Moyat M, Michetti P, Maillard MH, Velin D.
Macrophages promote epithelial repair through hepatocyte growth factor secretion. Clin
Exp Immunol 2013;174:60-72
5.
Perreau M, Rozot V, Welles HC, Belluti-Enders F, Vigano S, Maillard M, Dorta G, MazzaStalder J, Bart PA, Roger T, Calandra T, Nicod L, Harari A. Lack of Mycobacterium
tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease. Eur J
Immunol 2013;43:939-48
6.
Perreau M, Welles HC, Harari A, Hall O, Martin R, Maillard M, Dorta G, Bart PA, Kremer
EJ, Tartaglia J, Wagner R, Esteban M, Levy Y, Pantaleo G.DNA/NYVAC Vaccine Regimen
Induces HIV-Specific CD4 and CD8 T-Cell responses in Intestinal Mucosa. J Virol
2011;85:9854-62
7.
Velin D, Narayan S, Bernasconi E, Busso N, Ramelli G, Maillard MH, Bachmann D,
Pythoud C, Bouzourene H, Michetti P, So A. PAR2 Promotes vaccine-induced protection
against Helicobacter infection in mice. Gastroenterology 2011;141:1273-82
8.
Bernasconi E, Favre L, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, Croze E,
Velichko S, Parkinson J, Michetti P, Velin D. Granulocyte-macrophage colony stimulating
factor elicits bone-marrow derived cells that promote efficient colonic mucosal healing.
Inflamm Bowel Dis 2010;16:428-4
9.
Nguyen DD, Maillard MH, Cotta-de-Almeida V, Mizoguchi E, Klein C, Mizoguchi A, Bhan
AK and Snapper SB. Lymphocyte-Dependent and Th2 Cytokine-Associated Colitis in Mice
Deficient in Wiskott-Aldrich Syndrome Protein. Gastroenterology 2007;133:1188-97.
10.
Cotta-de-Almeida V, Maillard MH*, Westerberg L*, Onaldi D, Wachtel H, Meelu P, Chung
U-I, Xavier R, Alt FW and Snapper SB. WASP and N-WASP are critical for T cell
development. Proc Natl Acad Sci 2007;104:15424-9. *equal contribution
11.
Maillard MH*, Cotta-de-Almeida V*, Takeshima F, Nguyen DD, Michetti P, Nagler C,
Bhan AK and Snapper SB. The Wiskott Aldrich syndrome protein is required for the
function of CD4+CD25+Foxp3+ regulatory T cells. J Exp Med 2007;204:381-91. *equal
contribution
Related research highlight: Minton K. WASP helps TReg cells sting their prey. Nat Rev
Immunol 2007;7:253.
12.
Maillard M, Vu F, Pascual M, Michetti P, Felley C. New onset inflammatory bowel disease
post liver transplantation : Case Reports and Review of the Literature. Gastroenterol Clin
Biol 2006;30:1096-101.
Review articles and editorials
1.
Tissot F, Maillard MH. Clostridium Difficile Colitis : New treatment recommendations.
Rev Med Suisse 2014; 10: 913-919.
2.
Maitre S, Maniu CM, Buss G, Maillard MH, Spertini F, Ribi C. Food allergy or food
intolerance ? Rev Med Suisse 2014; 10: 846-53
3.
Godat S, Velin D, Aubert V, Nydegger A, Schoepfer AM, Maillard MH. An update on celiac
disease. Rev Med Suisse 2013;9:1584-9
4.
Maillard MH, Hiroz P, Wagner D, Prior J, Boubaker A, Pralong F, Dorta G, Nichita C.
Gastrointestinal neuroendocrine tumors: pleomorphic and often ignored. Rev Med Suisse
2012;8:1658-63.
5.
Kessler Brondolo V, Maillard MH, Delarive J, Mottet C, Michetti P. Inflammatory bowel
disease: a "survival kit" for general practitioners. Rev Med Suisse 2010;6:180-2, 184-5
6.
Felley C, Mottet C, Hess J, Maillard MH, Delarive J, Michetti P. Main therapeutic advances
in IBD in 2008. Rev Med Suisse 2009;5:185-6, 188-90, 192-4
7.
Felley C, Mottet C, Maillard MH, Hess J, Delarive J, Michetti P. Main therapeutic advances
in IBD in 2007. Rev Med Suisse 2008;4:200, 202-4.
8.
Maillard MH and Snapper SB. Teaching tolerance with a probiotic antigen delivery
system. Gastroenterology 2007,133:706-9
9.
Maillard MH. Les résolvines : nouveaux dérivés des acides gras polyinsaturés (oméga-3)
au potentiel thérapeutique dans les maladies inflammatoires intestinales. Rev Med Suisse
2006;2:2634-5
10.
Maillard MH. La pancréatite auto-immune : une nouvelle entité clinique. Rev Med Suisse
2006;2:1759-60
Book chapter Maillard MH and Snapper SB. Inflammatory Bowel Disease: Translating Basic Science into
Clinical Practice. Chapter 10: Cytokines and Chemokines in Mucosal Homeostasis. Wiley
Blackwell Edition, April 2010.
References
•
Prof. Darius Moradpour, Professor of Medicine. Chief of the Division of Gastroenterology
and Hepatology. Centre Hospitalier Universitaire Vaudois. University of Lausanne. Rue du
Bugnon 44. CH-1011 Lausanne. Phone :+41(0)21-3144723 (direct line); ++41(0)213144714 (secretary); +41(0)21-3144718 (Fax) [email protected]
•
Prof. Pierre Michetti, Crohn’s and Colitis Center, Clinique de la Source, Av. Jomini 8,
1004 Lausanne. Phone: +41(0)21-6443050. [email protected]
•
Prof. Scott B. Snapper, M.D., Ph.D. Director, Inflammatory Bowel Disease Center and
Basic & Translational Research (Gastroenterology, Children’s Hospital Boston, MA). Director,
Inflammatory Bowel Disease Research (Gastroenterology, Brigham and Women¹s Hospital,
Boston, MA). Associate Professor of Medicine, Harvard Medical School. Phone: (001) 617919-4973. [email protected] or [email protected]